:NCPAP versus HHFNC in treatment of premature infants with respiratory distress

Nasal continuous positive airway pressure (NCPAP) versus Humidified high flow nasal cannula (HHFNC) in treatment of premature infants with respiratory distress

Status

Active, not recruiting

Phases

Phase 2

Study type

Interventional

Source

IRCT

Registry ID

IRCT20151122025184N2

Enrollment

Registered

2021-07-29

Start date

2020-03-20

Completion date

Unknown

Last updated

2021-08-30

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

respiratory distress syndrome in premature infants. Respiratory distress syndrome of newborn

Interventions

Intervention 1: Intervention group: HHFNC GROUP:In this group, using an oxygen blender, treatment is given by giving oxygen at a suitable and moist concentration and with a flow of 4 to 7 liters per m

Eligibility

Sex/Gender

All

Age

No minimum to 3 Days

Inclusion criteria

Inclusion criteria: premature infants with GA fewer than 37 weeks premature infants with respiratory distress syndrome premature infants with respiratory distress syndrome who can extubate after surfactant therapy

Exclusion criteria

Exclusion criteria: congenital heart diseases asphyxia septic shock multiple anomaly

Design outcomes

Primary

Measure	Time frame
The extubation failure rate in two groups of NCPAP and HHFNC within 7 days after the intervention. Timepoint: within 7 days after INSURE(intubation and surfactant injection and extubation). Method of measurement: EXAMINATION AND STUDY OF FILES.;The length of oxygen requirement after surfactant therapy. Timepoint: during after surfactant therapy. Method of measurement: EXAMINATION AND STUDY OF FILES.	—

Measure

Time frame

The extubation failure rate in two groups of NCPAP and HHFNC within 7 days after the intervention. Timepoint: within 7 days after INSURE(intubation and surfactant injection and extubation). Method of measurement: EXAMINATION AND STUDY OF FILES.;The length of oxygen requirement after surfactant therapy. Timepoint: during after surfactant therapy. Method of measurement: EXAMINATION AND STUDY OF FILES.

—

Secondary

Measure	Time frame
Pneumotorax and air leaks of the plural space due to the two type of noninvasive ventilation during the period of receiving respiratory support. Timepoint: During the period of receiving noninvasive respiratory support (intervention). Method of measurement: EXAMINATION AND CXR AND STUDY OF FILES.;Intraventricular brain hemorrhage during the period of receiving respiratory support. Timepoint: During the period of receiving noninvasive respiratory support (the intervention). Method of measurement: examination and brain sonography.;Hospital length of stay. Timepoint: The total length of hospitalization of the studied neonates. Method of measurement: study of files.;Nasal trauma includes ulceration and necrosis during the period of receiving respiratory support. Timepoint: During the period of receiving respiratory support(the intervention). Method of measurement: inspection.	—

Measure

Time frame

Pneumotorax and air leaks of the plural space due to the two type of noninvasive ventilation during the period of receiving respiratory support. Timepoint: During the period of receiving noninvasive respiratory support (intervention). Method of measurement: EXAMINATION AND CXR AND STUDY OF FILES.;Intraventricular brain hemorrhage during the period of receiving respiratory support. Timepoint: During the period of receiving noninvasive respiratory support (the intervention). Method of measurement: examination and brain sonography.;Hospital length of stay. Timepoint: The total length of hospitalization of the studied neonates. Method of measurement: study of files.;Nasal trauma includes ulceration and necrosis during the period of receiving respiratory support. Timepoint: During the period of receiving respiratory support(the intervention). Method of measurement: inspection.

—

Countries

Iran (Islamic Republic of)

Contacts

Public Contactdr roya taheritafti

Shahid Beheshti University of Medical Sciences

royataheritafti@yahoo.com+98 21 8828 8037

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Feb 4, 2026